Last reviewed · How we verify
Salmeterol xinafoate/fluticasone propionate combination
Salmeterol xinafoate is a long-acting beta-2 agonist that relaxes airway smooth muscle, while fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation.
Salmeterol xinafoate is a long-acting beta-2 agonist that relaxes airway smooth muscle, while fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Salmeterol xinafoate/fluticasone propionate combination |
|---|---|
| Also known as | SERETIDE FLIXOTIDE |
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting beta-2 agonist / Inhaled corticosteroid combination |
| Target | Beta-2 adrenergic receptor (salmeterol); Glucocorticoid receptor (fluticasone propionate) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Salmeterol xinafoate binds to beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation with a duration of action of 12 hours. Fluticasone propionate acts as a glucocorticoid receptor agonist in the lungs, suppressing inflammatory responses including cytokine production and immune cell recruitment. Together, they provide both acute bronchodilation and chronic anti-inflammatory effects for asthma and COPD management.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Oral candidiasis
- Dysphonia
- Upper respiratory tract infection
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (PHASE3)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Asthma Research in Children and Adolescents
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: